Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;19(9):1067-1078.
doi: 10.1007/s12094-017-1648-8. Epub 2017 Mar 24.

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

J F Cueva  1 , S Antolín  2 , L Calvo  2 , I Fernández  3 , M Ramos  4 , L de Paz  5 , J G Mata  6 , R López  7 , M Constenla  8 , E Pérez  6 , A González  4 , M L Pellón  5 , S Varela  9 , T López  10
Affiliations

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

J F Cueva et al. Clin Transl Oncol. 2017 Sep.

Abstract

This Galician consensus statement is a joint oncologists/cardiologists initiative indented to establish basic recommendations on how to prevent and to manage the cardiotoxicity in breast cancer with the aim of ensuring an optimal cardiovascular care of these patients. A clinical screening of the patients before treatment is recommended to stratify them into a determined risk group based on their intrinsic cardiovascular risk factors and those extrinsic arose from breast cancer therapy, thereby providing individualized preventive and monitoring measures. Suitable initial and ongoing assessments for patients with low and moderate/high risk and planned treatment with anthracyclines and trastuzumab are given; also, measures aimed at preventing and correcting any modifiable risk factor are pointed out .

Keywords: Anticancer therapies; Breast cancer; Cardiotoxicity; Cardiovascular risk factors.

PubMed Disclaimer

Conflict of interest statement

Funding

This project was funded by an educational grant from TEVA Pharmaceutical Spain.

Conflict of interest

J. F. Cueva, T. López, S. Antolín, E. Pérez, J. García Mata, I. Fernández, L. Calvo and S. Varela report honoraria from TEVA during the conduct of the work. The rest of the authors did not declare their conflict of interests.

Figures

Fig. 1
Fig. 1
Adapted ACCF/AHA 2013 guideline for the management of heart failure. HT hypertension, LV left ventricular
Fig. 2
Fig. 2
Pyramid for management of cardiotoxicity risk. CVRF cardiovascular risk factors, CV cardiovascular
Fig. 3
Fig. 3
Sample algorithm for trastuzumab monitoring. (From The Oncologist [61], with permission). HF heart failure, LVEF left ventricular ejection fraction
See this image and copyright information in PMC

References

    1. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–1306. doi: 10.1016/j.mayocp.2014.05.013. - DOI - PMC - PubMed
    1. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–375. doi: 10.1093/jnci/djk064. - DOI - PubMed
    1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–939. doi: 10.1016/j.echo.2014.07.012. - DOI - PubMed
    1. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2902. doi: 10.1200/JCO.2005.05.827. - DOI - PubMed
    1. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–7826. doi: 10.1200/JCO.2005.13.300. - DOI - PubMed

Publication types

Substances

LinkOut - more resources